Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Investing activities: | ||
| Proceeds from maturities of available-for-sale marketable securities | 25,552 | 17,595 |
| Purchases of available-for-sale marketable securities | (8,485) | (27,546) |
| Purchases of property, equipment and leasehold improvements | (102) | — |
| Net cash provided by (used in) investing activities | 16,965 | (9,951) |
| Financing activities: | ||
| Proceeds from exercises of stock options | 222 | 718 |
| Proceeds from exercises of warrants | — | 8,220 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is Trevi Therapeutics, Inc.'s capex?
- Trevi Therapeutics, Inc. (TRVI) reported capex of $102K in Q1 2026.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Trevi Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude